Our pharmaceuticals companies offer medicines that treat many of the world's most serious and widespread diseases. In 2014, we invested $6.2 billion in pharmaceutical research and development for new medicines to treat these and many other diseases. It’s all part of our commitment to helping you and the ones you love lead longer, healthier lives. In 2017, for the fourth consecutive year, Fortune Magazine ranked Johnson & Johnson/Janssen number one in the Pharmaceuticals category on its annual World’s Most Admired Companies list.
The Pharmaceutical segment’s broad portfolio focuses on unmet medical needs across several therapeutic areas: cardiovascular & metabolism, immunology, infectious diseases & vaccines, neuroscience & pain, and oncology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use.
Janssen forms the largest part of our pharmaceutical segment and is one of the world’s leading research-based pharmaceutical companies. In the UK, Janssen employs more than 500 people.
The company is committed to delivering great medicines and has introduced a range of innovative treatments that can make an important difference to the lives of patients with serious health conditions such as schizophrenia, epilepsy, multiple myeloma and HIV/AIDS. Other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology and anaemia. Medicines developed by Janssen are used to treat around 1,500 million patients every year.